^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

1364P - ctDNA analysis of SAF-189s efficacy in ALK+ advanced non-small cell lung cancer (NSCLC)

Published date:
10/16/2023
Excerpt:
...a total of 143 NSCLC ALK-fusion positive pts had been enrolled and treated with SAF-189s…Of 25 pts who progressed with SAF-189s, two ALK mutations, G1202R and I1179T, were newly identified in 3 pts.
Trial ID: